SUBSCRIBE
SUBSCRIBE
News   Drug Development

Viewpoint Molecular Targeting(R) Presents Preclinical Data from VMT-

December 21, 2021 | 
1 min read

Viewpoint Molecular Targeting, Inc. announced the presentation of preclinical data from its theranostic in development, VMT-

  • Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumors
  • Preclinical data of VMT-
Preclinical
ACCESS Newswire
MORE ON THIS TOPIC
Digital overload and its impact on the human brain, showcasing fragmented thoughts, information overload. Abstract design art collage. Social media digital addiction, mental health, stress, anxiety
Neuropsychiatric disorders
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
June 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Businessmen look at the city from the outskirts.
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
People raise their hands. Leadership fights. The concept of fighting for rights. Revolution or protest. vector
Pancreatic cancer
Revolution’s second RAS blocker doubles chemo response rate in pancreatic cancer
June 25, 2026
 · 
2 min read
 · 
Tristan Manalac